Navigation Links
Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:6/19/2008

SAN DIEGO, June 19 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies announced today that InnerCool has entered into a exclusive commercialization agreement with N.G.C. Medical S.p.A., a leading Italian distributor of medical products. N.G.C. Medical primarily sells medical products to the intensive care, surgical and interventional cardiology markets. They also provide in-service management of surgical suites, intensive care units and interventional laboratories for a number of Italy's leading hospitals. The agreement covers InnerCool's CoolBlue(TM), a nurse-friendly and cost-effective surface cooling temperature modulation system, which was launched in the U.S. market during the fourth quarter 2007, as well as InnerCool's Celsius Control(TM) endovascular system and next-generation, high-performance RapidBlue(TM) system. Using N.G.C. Medical's marketing and sales force, sales of CoolBlue and RapidBlue consoles and disposables are expected to begin in Italy in the third quarter of 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"We are pleased to have this distribution agreement with N.G.C. Medical," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies. "This new Italian partnership, along with our recent distribution agreements for Australia, New Zealand, Germany, Switzerland and Austria are consistent with our strategy of accelerating the growth of InnerCool's temperature modulation business in a strategic, efficient and cost-effective manner by establishing relationships with existing specialized intern
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
4. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
9. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
10. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
11. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Cytokinetics, Incorporated ... on February 28 with patients and health care advocates ... for Rare Disease Day®. Rare Disease Day is ... calling attention to the special challenges faced by patients ... , “Cytokinetics is proud to stand alongside patients and ...
(Date:2/26/2015)... S&P Capital IQ (MHFI) announced today that ... MabVax Therapeutics Holdings Inc . MabVax ... company focused on the development of vaccine and antibody-based ... of cancer. MabVax has discovered a pipeline of human ... generated by patients who have been immunized against targeted ...
(Date:2/26/2015)... TORONTO , Feb. 26, 2015 /PRNewswire/ - SQI ... SQIDF), a life sciences company that develops and commercializes ... reported its financial and operational results for the fiscal ... this press release are in Canadian dollars (CAD), unless ... Company continued to win new business from our existing ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Sept. 21 Nile Therapeutics Inc., (OTC,Bulletin Board: ... cardiovascular disease, is pleased to announce the,appointments of ... Jennifer,Hodge as the Vice President of Development. ... our Chief Operating Officer,and was appointed Chief Financial ...
... of Physics Dr. Satyendra Kumar recently was honored ... Directors Award for Excellence for recognition of exceptional ... matter physics proposals. In all, seven program directors ... Arlington, Va. , The NSF Directors Award ...
... China, Sept. 20 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... it has launched its newest product, Shining ... the Shanghai and Changchun markets. Shining ...
Cached Biology Technology:Nile Therapeutics, Inc. Adds to Executive Management Team 2Nile Therapeutics, Inc. Adds to Executive Management Team 3Nile Therapeutics, Inc. Adds to Executive Management Team 4China-Biotics, Inc. Launches Shining Probiotics Protein Powder 2
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... 2013 BioNano Genomics , the developer of the Irys™ ... Fahim Amini , Ph.D. as vice president, Commercial Operations EMEA. ... System, making it possible for researchers and clinicians in ... Africa to access BioNano,s recently launched Irys platform. ...
... BioPharma, Inc. today announced that it has begun oral dosing ... ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside ... RSV infection. It is the only known nucleoside analog ... ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV ...
... uses pedometers to monitor how much people move throughout the ... a particular problem for office workers, and helping participants drop ... minutes a day, the fact that they,re sitting and not ... the day is in and of itself detrimental to their ...
Cached Biology News:BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA 2BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA 3Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection 2Study: Pedometer program helps motivate participants to sit less, move more 2
...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Fluorescence Preserving Media, 100 mL...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
Biology Products: